BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer
December 6th 2023The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.
Read More
Frontline VR-CAP Is Effective and Well Tolerated in MZL
October 23rd 2023Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.
Read More
Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.
Read More
Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma
September 28th 2023Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.
Read More
Durvalumab Associated With Lower Real-World PFS in EGFR-Mutated NSCLC Vs EGFR Wild-Type NSCLC
September 11th 2023Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.
Read More